Pharmaceuticals

Immunology Biosimilars Market Growth Projection: Expected to Surpass $15.3 Billion by 2030 at 12.8% CAGR

February 16, 2026March 11, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the immunology biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Immunology Biosimilars Market?

In recent years, the immunology biosimilars market has experienced rapid growth in its size. It is projected to expand from $8.35 billion in 2025 to $9.45 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.2%. The factors contributing to this historical expansion include the high cost of original biologics, limited availability of biosimilar alternatives, the growing prevalence of autoimmune diseases, increasing hospital and clinical adoption of biologics, and stringent regulatory approvals for biosimilars.

The immunology biosimilars market size is projected for significant expansion in the coming years. This market is anticipated to reach $15.3 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.8%. Factors contributing to this growth during the forecast period include the advancement of biosimilar molecules, an increase in homecare and outpatient treatment availability, greater regulatory alignment, heightened patient understanding and acceptance, and the proliferation of online and hospital pharmacy distribution networks. Key trends observed within the forecast timeframe encompass the growing embrace of monoclonal antibody biosimilars, an uptick in the utilization of fusion protein biosimilars, the broadening scope of recombinant protein therapies, an expanding market for interferon-based treatments, and improved accessibility to cost-effective immunology treatments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25789&type=smp

What Drivers Are Supporting Technological Adoption In The Immunology Biosimilars Market?

A rise in chronic immunological conditions is anticipated to boost the expansion of the immunology biosimilars market in the future. These conditions are persistent ailments where the immune system operates improperly, either assaulting the body’s own tissues or not providing adequate defense. This increase stems from a growing population suffering from long-term immune system disorders that necessitate ongoing treatment, proactive management of the disease, and continuous healthcare assistance. Immunology biosimilars assist in managing chronic immunological conditions by offering cost-effective and efficient treatment options, facilitating enduring disease management, and enhancing patient accessibility to vital therapies designed to regulate immune system irregularities. As an illustration, in November 2023, the Multiple Sclerosis International Federation (MSIF), a UK-based international nonprofit organization focused on global MS research and advocacy, reported that approximately 2.9 million individuals globally had multiple sclerosis in 2023. Consequently, the expanding occurrence of chronic immunological conditions is stimulating growth within the immunology biosimilars market.

Which Segments Are Contributing To The Growth Of The Immunology Biosimilars Market?

The immunology biosimilars market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Fusion Proteins, Recombinant Proteins, Interferons, Other Biosimilar Immunomodulators

2) By Disease: Inflammatory Bowel Disease, Arthritis, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End User: Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs)

Subsegments:

1) By Monoclonal Antibodies: Anti-Tumor Necrosis Factor Agents, Anti-Interleukin-6 Agents, Anti-Cluster of Differentiation 20 Agents, Anti-Interleukin-12/23 Agents, Other Monoclonal Antibodies

2) By Fusion Proteins: Etanercept Biosimilars, Other Fusion Protein Biosimilars

3) By Recombinant Proteins: Recombinant Human Insulin, Recombinant Human Growth Hormone, Recombinant Human Erythropoietin, Other Recombinant Protein Biosimilars

4) By Interferons: Interferon Alpha, Interferon Beta, Interferon Gamma

5) By Other Biosimilar Immunomodulators: Interleukin Inhibitors, Janus Kinase Inhibitors, Other Immunomodulatory Biosimilars

Which Market Trends Are Opening Growth Opportunities In The Immunology Biosimilars Market?

Leading companies within the immunology biosimilars market are concentrating on developing next-generation biosimilar innovations. These include anticipated interchangeability designation, advanced formulations with enhanced stability, and novel delivery systems, all aimed at providing patients with more accessible and effective treatment options. An anticipated interchangeability designation indicates that the biosimilar is expected to meet regulatory standards, permitting its substitution for the reference biologic at the pharmacy level without requiring intervention from the prescriber. For example, in February 2025, Sandoz Group AG, a Switzerland-based pharmaceutical company, introduced Pyzchiva (ustekinumab-ttwe), a biosimilar to Stelara, for managing chronic autoimmune conditions such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This launch, conducted in collaboration with Samsung Bioepis Co. Ltd., a South Korea-based biopharmaceutical company, highlights Sandoz’s commitment to broadening access to immunology biosimilars by offering a cost-effective and patient-centric therapy that includes multiple dosing options, extended stability, and the unique feature of being re-refrigerable after initial refrigeration.

Who Are The Major Companies Operating In The Immunology Biosimilars Market?

Major companies operating in the immunology biosimilars market are Pfizer Inc., Novartis AG, Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Gedeon Richter Plc, Celltrion Inc., Biocon Ltd., Innovent Biologics Inc., Biocad, Mabion S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/immunology-biosimilars-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Immunology Biosimilars Market?

North America was the largest region in the immunology biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Immunology Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25789&type=smp

Browse Through More Reports Similar to the Global Immunology Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795